KYE Pharmaceuticals Inc. nhasi yazivisa kuti yaendesa New Drug Submission (NDS) kuHealth Canada kuti iongororwe uye kubvumidzwa kweAccrufer® (ferric maltol).
Kana ikatenderwa, Accrufer® ingangove yekutanga kunyorerwa chete nesimbi yekurapa kurapwa yakabvumidzwa neHealth Canada uye kubvumidzwa kwekushambadzira kweAccrufer® kunotarisirwa kunge kuri mukati mehafu yekutanga ya2023.
Doug Reynolds, Mutungamiriri weKYE, akati: "Zvikwata zveShield neKYE zvakashanda nesimba kuunganidza Canada NDS mukati memwedzi yakati wandei uye ndinofara zvikuru kuti ndawana chiitiko ichi."
José A. Menoyo, MD, Chief Medical Officer weShield, akawedzera kuti: “Tiri kufara nekufambira mberi kuri kuitwa mukubatana neKYE kubva pakasainwa chibvumirano cherezinesi muna Ndira. Masangano ese ari maviri akaratidza kubatana kwakanakisa uye anofambiswa kuita kuti Accrufer® iwanikwe kune varwere muCanada vane kushaya simbi nekukurumidza sezvinobvira. Shield Therapeutics yakazvipira kuunza Accrufer®/Feraccru® kuvarwere vane iron inoshomeka pasi rose, uye Canada chinhu chakakosha pachinangwa ichocho.
ZVOKUBVA MUNYAYA INO:
- “Chikwata cheShield neKYE chakashanda nesimba zvikuru kuunganidza NDS yekuCanada mukati memwedzi yakati wandei uye ndinofara zvikuru kuti ndakwanisa kuita chinhanho ichi.
- Shield Therapeutics yakazvipira kuunza Accrufer®/Feraccru® kuvarwere vane iron inoshaya pasi rose, uye Canada chinhu chakakosha chechinangwa ichocho.
- nhasi yazivisa kuti yaendesa New Drug Submission (NDS) kuHealth Canada kuti iongororwe uye kubvumidzwa kweAccrufer® (ferric maltol).